Login
Search
Search
0 Dates
2025
2024
2023
2022
2021
2020
2019
2018
0 Events
CPC 2018
CPC 2019
Curso de Atualização em Medicina Cardiovascular 2019
Reunião Anual Conjunta dos Grupos de Estudo de Cirurgia Cardíaca, Doenças Valvulares e Ecocardiografia da SPC
CPC 2020
CPC 2021
CPC 2022
CPC 2023
CPC 2024
CPC 2025
0 Topics
A. Basics
B. Imaging
C. Arrhythmias and Device Therapy
D. Heart Failure
E. Coronary Artery Disease, Acute Coronary Syndromes, Acute Cardiac Care
F. Valvular, Myocardial, Pericardial, Pulmonary, Congenital Heart Disease
G. Aortic Disease, Peripheral Vascular Disease, Stroke
H. Interventional Cardiology and Cardiovascular Surgery
I. Hypertension
J. Preventive Cardiology
K. Cardiovascular Disease In Special Populations
L. Cardiovascular Pharmacology
M. Cardiovascular Nursing
N. E-Cardiology / Digital Health, Public Health, Health Economics, Research Methodology
O. Basic Science
P. Other
0 Themes
01. History of Cardiology
02. Clinical Skills
03. Imaging
04. Arrhythmias, General
05. Atrial Fibrillation
06. Supraventricular Tachycardia (non-AF)
07. Syncope and Bradycardia
08. Ventricular Arrhythmias and Sudden Cardiac Death (SCD)
09. Device Therapy
10. Chronic Heart Failure
11. Acute Heart Failure
12. Coronary Artery Disease (Chronic)
13. Acute Coronary Syndromes
14. Acute Cardiac Care
15. Valvular Heart Disease
16. Infective Endocarditis
17. Myocardial Disease
18. Pericardial Disease
19. Tumors of the Heart
20. Congenital Heart Disease and Pediatric Cardiology
21. Pulmonary Circulation, Pulmonary Embolism, Right Heart Failure
22. Aortic Disease
23. Peripheral Vascular and Cerebrovascular Disease
24. Stroke
25. Interventional Cardiology
26. Cardiovascular Surgery
27. Hypertension
28. Risk Factors and Prevention
29. Rehabilitation and Sports Cardiology
30. Cardiovascular Disease in Special Populations
31. Pharmacology and Pharmacotherapy
32. Cardiovascular Nursing
33. e-Cardiology / Digital Health
34. Public Health and Health Economics
35. Research Methodology
36. Basic Science
37. Miscellanea
0 Resources
Abstract
Slides
Vídeo
Report
CLEAR FILTERS
Impact of the HeartMate 3 on Quality of Life in Heart Failure: A Study Using EQ-5D-5L
Session:
SESSÃO DE POSTERS 22 - LVAD / TRANSPLANTAÇÃO CARDÍACA
Speaker:
Inês Coutinho Dos Santos
Congress:
CPC 2025
Topic:
D. Heart Failure
Theme:
10. Chronic Heart Failure
Subtheme:
10.4 Chronic Heart Failure – Treatment
Session Type:
Cartazes
FP Number:
---
Authors:
Inês Coutinho Dos Santos; Márcia Presume; Cátia Sampaio; Sérgio Maltês; Bruno Rocha; Catarina Brízido; Christopher Strong; Marta Marques; Carlos Aguiar
Abstract
<p style="text-align:justify"><strong>Background</strong>: Advanced heart failure (HF) significantly impairs quality of life (QoL) due to severe symptom burden and functional limitations. Implantation of durable left ventricular assist devices (LVADs) such as HeartMate 3™ (HM3) has been shown to prolong life and improve QoL in eligible patients.</p> <p style="text-align:justify"><strong>Aim</strong>: To assess and compare QoL in advanced HF patients before and after HM3 implantation using the EuroQoL-5 Dimensions-5 Levels (EQ-5D-5L) questionnaire.</p> <p style="text-align:justify"><strong>Methods</strong>: This cohort study included all patients currently or previously under HM3 support, followed at our center. QoL was assessed with the Portuguese telephone version of EQ-5D-5L, and responses were converted into scores using the Portuguese value set. Normality tests guided the selection of paired-samples t-test and Wilcoxon Signed Rank test for comparisons of pre- and post-HM3 scores. The latter was also compared with the societal values that serve as a reference score for the Portuguese population. Statistical significance was set at p < 0.05.</p> <p style="text-align:justify"><strong>Results</strong>: Fourteen patients (mean age 55.9 years) with severe cardiac dysfunction (mean LVEF 20.0%±7.1%) were included. The most frequent etiology was ischaemic (57.1%), followed by dilated (28.6%) cardiomyopathy. Most patients were in INTERMACS profiles 2 or 3 at implantation, with 57.1% receiving HM3 as a bridge to transplantation and 14.3% with the goal of destination therapy. After a median LVAD duration of 19.5 months [16.0-32.0] months, QoL showed significant improvement: median EQ-VAS rose from 20.0 to 70.0 (p=0.008), and mean EQ-5D-5L index increased from 0.347 to 0.895 (p=0.001, 95% CI 0.230-0.867). Domain analysis revealed significant reductions in problems related to mobility (p=0.006), usual day activities (p=0.003), pain/discomfort (p=0.044) and anxiety/depression (p=0.041), while self-care limitations remained unchanged. Post-HM3 implantation QoL was comparable to the general Portuguese population (p=0.388) and superior to the chronic disease subgroup (p=0.011).</p> <p style="text-align:justify"><strong>Conclusion</strong>: Advanced HF patients receiving HM3 experience significant QoL improvements, achieving levels similar to the general Portuguese population and exceeding those of patients with chronic diseases. These findings align with existing literature, including the HM3 ELEVATE registry.</p>
Slides
Our mission: To reduce the burden of cardiovascular disease
Visit our site